Publicaciones en colaboración con investigadores/as de Universitat de València (20)

2021

  1. Gender Differences in the Presentation and Outcomes of Hospitalized Patients With COVID-19

    Journal of hospital medicine, Vol. 16, Núm. 6, pp. 349-352

2020

  1. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis

    Frontiers in Endocrinology, Vol. 11

2019

  1. Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)

    Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130

  2. Modulation of saliva microbiota through prebiotic intervention in HIV-Infected individuals

    Nutrients, Vol. 11, Núm. 6

2018

  1. Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial

    Hipertensión y riesgo vascular, Vol. 35, Núm. 3, pp. 119-129

  2. Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota

    AIDS, Vol. 32, Núm. 10, pp. 1229-1237

  3. Interplay between gut microbiota metabolism and inflammation in HIV infection

    ISME Journal, Vol. 12, Núm. 8, pp. 1964-1976

2017

  1. Cardiovascular toxicity of abacavir: A clinical controversy in need of a pharmacological explanation

    AIDS, Vol. 31, Núm. 13, pp. 1781-1795

  2. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

    Mucosal Immunology, Vol. 10, Núm. 5, pp. 1279-1293

2016

  1. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: Rationale for further study on blood pressure targets of antihypertensive treatment after stroke

    Journal of Hypertension, Vol. 34, Núm. 3, pp. 393-396

  2. Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals

    EBioMedicine, Vol. 8, pp. 203-216

  3. HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases

    Scientific Reports, Vol. 6

2015

  1. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

    Mucosal Immunology, Vol. 8, Núm. 4, pp. 760-772

  2. Explorando el contexto del tratamiento antihipertensivo en Atención Primaria. Estudio SIMPLITENS

    Hipertension y Riesgo Vascular, Vol. 32, Núm. S1, pp. 3-11

2014

  1. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1888-1897

  2. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1741-1750

  3. Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study

    Clinica e Investigacion en Arteriosclerosis, Vol. 26, Núm. 3, pp. 107-114

2012

  1. Evaluation of health-related quality of life according to carbohydrate metabolism status: A Spanish population-based study (Di@bet.es Study)

    International Journal of Endocrinology, Vol. 2012

2005

  1. Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients

    Pharmacogenomics Journal, Vol. 5, Núm. 1, pp. 14-20

2004

  1. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: Recommendations of HDL Forum

    American Journal of Cardiovascular Drugs, Vol. 4, Núm. 5, pp. 299-314